Cibus to Participate in Alliance Global Partner’s Annual Virtual Healthcare Company Showcase

SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Peter Beetham, Co-Founder, President, and Interim Chief Executive Officer, will host a presentation at the AGP Annual Virtual Healthcare Company Showcase.

During the presentation, Dr. Beetham will discuss the Company's progress in advancing its gene-editing technology platform, recent regulatory developments supporting agricultural innovation, and Cibus' commercialization strategy for its productivity trait pipeline.

Presentation Details
Date: Wednesday, May 21, 2025
Time: 4:40 p.m. ET (1:40 p.m. PT)
Webcast link: https://us02web.zoom.us/webinar/register/WN_jB1HgKLvQFmUfC6VBT11mw

About Cibus

Cibus is a leader in gene edited productivity traits that address critical productivity and sustainability challenges for farmers such as diseases and pests which the United Nations estimates cost the global economy approximately $300 billion annually. Cibus is not a seed company. It is a technology company that uses gene editing to develop and license traits to seed companies in exchange for royalties on seed sales. Cibus' long-term focus is productivity traits for farmers for the major global row crops with large acreage such as canola, corn, rice, soybean, and wheat. Cibus is a technology leader in high-throughput gene editing technology that is expected to enable it to develop and commercialize plant traits at a fraction of the time and cost of conventional breeding. Cibus has developed a current pipeline of five productivity traits including important traits for weed management in Rice, Pod Shatter Reduction, and Sclerotinia (disease) resistance, which are its near-term focus.

CIBUS CONTACTS:

INVESTOR RELATIONS
Karen Troeber
ktroeber@cibus.com
858-450-2636

Jeff Sonnek – ICR
jeff.sonnek@icrinc.com

MEDIA RELATIONS
Colin Sanford
colin@bioscribe.com
203-918-4347

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.